MOLECULAR FEATURES OF BORTEZOMIB-INDUCED NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA

Background. The regimens of therapy with bortezomib have significantly improved the survival among patients with multiple myeloma (MM). However, the development of peripheral polyneuropathy (PP) resulting from treatment using proteasome inhibitors is still an undesirable event. Risk factors for PP in MM patients include old age, previous neuropathy and use of neurotoxic drugs. Recent studies have established the presence of a genetic component in the mechanism of developing bortezomib-induced neurotoxicity. However, there are conflicting opinions on the role of genetic characteristics in predicting the risk of treatment-induced neuropathy development.

Aim. To identify the risk group of bortezomib-induced PP based on the analysis of gene polymorphism of the immune response in patients with newly-diagnosed MM.

Materials and methods. A study of the association of 20 polymorphic loci of 14 immune response genes in 46 MM patients was conducted using a candidate gene identification approach. All the patietns were receiving VCD therapy with bortezomib.

Results. The distribution of single nucleotide polymorphisms was compared in groups of patients with the presence and absence of PP. It is found that homozygous carriers of the wild type allele of the genes TLR6 (Ser249Pro) (p = 0.006), IL1β (G-1473C) (p = 0.04), IL4 (C-589T) (p = 0.04), as well as haplotype carriers with the mutant allele of the gene IL10 (G-1082A) (p = 0.04) and with the wild type allele gene IL2 (T-330G) (p = 0.01) were significantly more frequent among PP patients.

Сonclusion. Our results have confirmed the contribution of the genetic component to the risk of developing bortezomibinduced neuropathy. These findings can be used for individualization of therapeutic approaches to the treatment of MM patients.

1. García-Sanz R., Corchete L.A., Alcoceba M., et al. GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol. Oncol. 2016; 9: 1–6. DOI: 10.1002/hon.2337

2. Starobova H., Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front. Mol. Neurosci. 2017; 10: 174. DOI: 10.3389/ fnmol.2017.00174

3. Campo C., Da Silva Filho M.I., Weinhold N., et al. Genetic susceptibility to bortezomib-induced peripheral neuroropathy: replication of the reported candidate susceptibility loci. Neurochem. Res. 2017; 42(3): 925–31. DOI: 10.1007/ s11064-016-2007-9

4. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59(11): 2615–22.

5. Becker P.S. Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma. J. Clin. Oncol. 2011; 29(7): 783–6. DOI: 10.1200/ JCO.2010.33.4771

6. Boyette-Davis J.A., Walters E.T., Dougherty P.M. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag. 2015; 5(4): 285–96. DOI: 10.2217/pmt.15.19

7. Magrangeas F., Kuiper R., Avet-Loiseau H., et al. A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European patients with multiple myeloma. Clin. Cancer Res. 2016; 22(17): 4350–5. DOI: 10.1158/1078-0432.CCR-15-3163

8. Argyriou A.A., Cavaletti G., Bruna J., et al. Bortezomib-induced peripheral neurotoxicity: an update. Arch. Toxicol. 2014; 88(9): 1669–79. DOI: 10.1007/ s00204-014-1316-5

9. Meregalli C. An Overview of Bortezomib-Induced Neurotoxicity. Toxics. 2015; 3: 294–303. DOI: 10.3390/toxics3030294

10. Landowski T.H., Megli C.J., Nullmeyer K.D., et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005; 65(9): 3828–36.

11. Ghelardini C., Menicacci C., Cerretani D., Bianchi E. Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat. Neuropharmacology. 2014; 86: 294–300. DOI: 10.1016/j.neuropharm.2014.08.004

12. Alé A., Bruna J., Calls A., et al. Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology. 2016; 55: 58–64. DOI: 10.1016/j.neuro.2016.05.004

13. Bilińska M., Usnarska-Zubkiewicz L., Pokryszko-Dragan A. Bortezomibinduced painful neuropathy in patients with multiple myeloma. Contemp. Oncol. (Pozn). 2013; 17(5): 421–6. DOI: 10.5114/wo.2013.37214

14. Morawska M., Grzasko N., Kostyra M., et al. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol. Oncol. 2015; 33(4): 113–9. DOI: 10.1002/hon.2149

15. Nazarova E.L., Shardakov V.I. Polymorphism of Toll-like receptor genes in hematological malignancies. Citokiny i vospalenie. 2017; 16(4): 13–20 (In Russian).

16. Nazarova E.L., Shardakov V.I. Role of polymorphisms of Toll-like receptors signaling pathway genes in the development of hematological malignancies. Uchenye zapiski Sankt-Peterburgskogo gosudarstvennogo medicinskogo universiteta imeni akademika I.P. Pavlova. 2017. 24(3): 7–21 (In Russian).

17. Favis R., Sun Y., van de Velde H., et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet. Genomics. 2011; 21(3): 121–9. DOI: 10.1097/FPC.0b013e3283436b45

18. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975; 36(3): 842–54.

19. Mitra A.K., Harding T., Mukherjee U.K., et al. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J. 2017; 7(6): 581. DOI: 10.1038/bcj.2017.56

20. Corthals S.L., Kuiper R., Johnson D.C., et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica. 2011; 96(11): 1728–32. DOI: 10.3324/haematol.2011.041434

21. Campo C., da Silva Filho M.I., Weinhold N., et al. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients. Hematol. Oncol. 2017; 3: 1–6. DOI: 10.1002/hon.2391

22. Beutler A.S., Kulkarni A.A., Kanwar R., et al. Sequencing of Charcot — Marie — Tooth disease genes in a toxic polyneuropathy. Ann. Neurol. 2014; 76(5): 727–37. DOI: 10.1002/ana.24265

23. Weis J., Claeys K.G., Roos A., et al. Towards a functional pathology of hereditary neuropathies. Acta Neuropathol. 2017; 133(4): 493–515. DOI: 10.1007/ s00401-016-1645-y

24. Domingo-Domènech E., Benavente Y., González-Barca E., et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the urvival of patients with lymphoid neoplasms. Haematologica. 2007; 92(11): 1475–81.

25. Mutlu P., Yalcin S., Elci P., et al. Association of -174G/C interleukin-6 gene polymorphism with the risk of chronic lymphocytic, chronic myelogenous and acute myelogenous leukemias in Turkish patients. J. BUON. 2014; 19(3): 787–91.

26. Moore E.E., Presnell S., Garrigues U., et al. Expression of IL-17B in neurons and evaluation of its possible role in the chromosome 5q-linked form of CharcotMarie-Tooth disease. Neuromuscul. Disord. 2002; 12(2): 141–50.

27. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 2007; 137(1): 194–9.

28. Rudzianskiene M., Inciura A., Juozaityte E., et al. The role of single nucleotide polymorphism of IL-6 and IL-10 cytokine on pain severity and pain relief after radiotherapy in multiple myeloma patients with painful bone destructions. Genetika. 2014; 46(2): 455–69.

29. Nazarova E.L., Demyanova V.T., Shardakov V.I., et al. The association a number of innate immunity genes polymorphism with the risk of developing multiple myeloma and chronic lymphocytic leukemia. Gematologiya i transfuziologiya. 2016; 61(4): 183–9 (In Russian).

30. Zheng C., Huang D., Liu L., et al. Interleukin-10 gene promoter polymorphism in multiple myeloma. Int. J. Cancer. 2001; 95(3): 184–8.

31. Mazur G., Bogunia-Kubik K., Wróbel T., et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol. Lett. 2005; 96(2): 241–6.

32. Brown E.E., Lan Q., Zheng T., et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int. J. Cancer. 2007; 120: 2715–22. DOI: org/10.1002/ijc.22618

33. Churnosov M.I., Sirotina S.S., Tikunova T.S., et al. Cytokine’s genes and chronic lymphocytic leukemia. Moscow: RAMN; 2014: 132 (In Russian).

34. Watanabe T., Mitsuhashi M., Sagawa M., et al. Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J. 2013; 3: 150. DOI: 10.1038/ bcj.2013.47

35. Isaza-Correa J.M., Liang Z., van den Berg A., et al. Toll-like receptors in the pathogenesis of human B cell malignancies. J. Hematol. Oncol. 2014; 7: 57–67. DOI: 10.1186/s13045-014-0057-5

36. National Center for Biotechnology Information. Available at: http://www. ncbi.nlm.nih.gov/.

37. Ellyard J.I., Simson L., Parish C.R. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens. 2007; 70(1): 1–11. DOI: 10.1111/j.1399- 0039.2007.00869.x